KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Amortization - Intangibles: 2017-2024

Historic Amortization - Intangibles for BeOne Medicines (ONC) over the last 6 years, with Jun 2024 value amounting to $1.2 million.

  • BeOne Medicines' Amortization - Intangibles rose 14.49% to $1.2 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.6 million, marking a year-over-year increase of 91.06%. This contributed to the annual value of $7.2 million for FY2023, which is 82.07% up from last year.
  • According to the latest figures from Q2 2024, BeOne Medicines' Amortization - Intangibles is $1.2 million, which was down 0.51% from $1.2 million recorded in Q1 2024.
  • Over the past 5 years, BeOne Medicines' Amortization - Intangibles peaked at $3.0 million during Q4 2023, and registered a low of $187,000 during Q3 2020.
  • For the 3-year period, BeOne Medicines' Amortization - Intangibles averaged around $1.4 million, with its median value being $1.0 million (2022).
  • In the last 5 years, BeOne Medicines' Amortization - Intangibles tumbled by 43.50% in 2020 and then spiked by 442.55% in 2022.
  • Over the past 5 years, BeOne Medicines' Amortization - Intangibles (Quarterly) stood at $188,000 in 2020, then skyrocketed by 335.64% to $819,000 in 2021, then climbed by 18.32% to $969,000 in 2022, then spiked by 205.16% to $3.0 million in 2023, then climbed by 14.49% to $1.2 million in 2024.
  • Its Amortization - Intangibles was $1.2 million in Q2 2024, compared to $1.2 million in Q1 2024 and $3.0 million in Q4 2023.